Post‐Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing
Clinical Pharmacology & Therapeutics · 2026-09 · 120 (3) · 667-672
DOI: 10.1002/cpt.70328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 15.05.2026. Verfasst von Ian T T Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Drug Approval, Pediatrics, Off-Label Use. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
The Pediatric Research Equity Act mandates new drugs be tested in children before Food and Drug Administration (FDA) approval, though roughly one‐fifth of these drugs are granted complete waivers from pediatric testing. With the high prevalence of these waivers, US children may be at risk of being treated by drugs without pediatric testing (and therefore with unclear risk–benefit profiles). We evaluated how often drugs granted pediatric testing waivers are prescribed in US children using a large commercial claims database. Using public FDA data, we identified drugs granted pediatric testing waivers from 2007 to 2022 that did not report pediatric testing prior to FDA approval. We used the Merative MarketScan Commercial Database to determine monthly pediatric users for the first 36 months after approval. We defined “pediatric users” as the number of unique pediatric patients with ≥1 dispensing in a month. Among 291 drugs granted waivers from pediatric testing, 147 (51%) had observable pediatric use in the first 3 years following approval. Median summed users was 17 (interquartile range [IQR], 3–102), with median 0.47 users/month (IQR, 0.08–2.83). Among the top 20 most‐used drugs, pediatric users ranged from 508 (valsartan/hydrochlorothiazide) to 22,111 (conjugated estrogen cream) (median 1,050.5; IQR, 709.5–1,690.8), with a median of 29.2 users/month (IQR, 19.7–47.0). Among drugs granted waivers from pediatric trials, half have observable off‐label use in children in the 3 years after FDA approval. Routine clinical use evidence from these prescriptions could be collected to inform drug labeling updates, and some drugs have sufficient use to make post‐approval pediatric studies feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pediatrics, University of Illinois Chicago, Chicago, Illinois, USA.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Ian T T Liu, Timothy J Savage, Theodore N Tsacogianis, Aaron S Kesselheim, Ameet Sarpatwari
Förderung
- NICHD NIH HHS
Zitieren
APA
Liu, I. T. T., Savage, T. J., Tsacogianis, T. N., Kesselheim, A. S., & Sarpatwari, A. (2026). Post‐Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing. Clinical Pharmacology & Therapeutics, 120(3), 667-672. https://doi.org/10.1002/cpt.70328
Vancouver
Liu ITT, Savage TJ, Tsacogianis TN, Kesselheim AS, Sarpatwari A. Post‐Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing. Clinical Pharmacology & Therapeutics. 2026;120(3):667-672. doi:10.1002/cpt.70328
BibTeX
@article{Liu2026,
author = {Liu, Ian T T and Savage, Timothy J and Tsacogianis, Theodore N and Kesselheim, Aaron S and Sarpatwari, Ameet},
title = {Post‐Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {120},
number = {3},
pages = {667--672},
doi = {10.1002/cpt.70328}
}
EUVIMED